William Ragatz
Chairman
As President and CEO of Sentrimed, Bill Ragatz has significant and broad commercial experience in addition to expertise in building strong organizations and successfully developing and launching pipeline assets. Bill has over 25 years of experience in the pharmaceutical/biotech industry. Most recently, Bill was SVP, Head of Commercial at Viela Bio, where he built and led the global commercial organization and created the overall commercial vision for bringing pipeline assets to market. Bill was integral to Viela’s IPO and its successful acquisition by Horizon Therapeutics. Throughout his career, Bill has led numerous product launches spanning a range of therapeutic areas, including oncology, respiratory, and cardiovascular disease. Bill earned his MBA from the Fuqua School of Business at Duke University.
Dr. Jack Goldberg, MD
Dr. Jack Goldberg serves as Chief Medical Officer for Sentrimed. With over 40 years of experience in running clinical trials in oncology, particularly in blood cancer, he has deep ties to the oncology community and is the author of over 70 peer-reviewed publications. Earlier in his career, Dr. Goldberg established the Cooper Cancer Institute in Camden New Jersey in 1988, and the Abramson Comprehensive Cancer Center at Penn Presbyterian in 2002. He also established and has received funding from the NIH for the Community Clinical Oncology Program of New Jersey. Dr. Goldberg is a past Chairperson of the NCI Biology and Immunology Contracts Review Committee. He served as the American Cancer Society Professor of Clinical Oncology from 1992 to 2002. He is certified by the American Board of Internal Medicine, the American Subspecialty Board of Hematology, and the American Subspecialty Board of Oncology. Dr. Goldberg serves on the board of the American Cancer Society Camden County and has been an active member of the Cancer and Acute Leukemia Group B and the Leukemia Intergroup.
Dr. Bradley S. Galer, MD
Brad has over 20 years of experience leading and building global drug development and medical affairs teams focused in pain and epilepsy. Currently he is Chief Medical Officer at Rapport Therapeutics and has held prior positions as Executive Vice President and Chief Medical Officer at Zogenix, President of the Pain Group at Nuvo Research, and Senior Medical Officer for Endo Pharmaceuticals. He and his teams provided clinical and scientific leadership for the development and marketing of rare epilepsy and analgesic medications, including Fintepla®, Lidoderm®, Pennsaid®, and Frova®. Prior to joining industry, Dr. Galer held numerous academic and clinical appointments. He has over 150 publications in epilepsy and pain management. Dr. Galer completed his medical doctorate and a neurology residency at Albert Einstein College of Medicine in New York, and two pain fellowships at Memorial Sloan Kettering Cancer Center in New York and the University of California San Francisco and was on faculty at the University of Washington School of Medicine.
Tabbetha Dobbins
Tabbetha is the Dean of the School of Graduate Studies at Rowan University. She served as Vice President for Research and Dean of the Graduate School at Rowan University from 2020 to 2023. She is also a full professor in the Dept. of Physics & Astronomy at Rowan University where she continues to do cutting edge research in applying synchrotron x-ray and neutron analysis to modern engineering problems in carbon nanotubes, gold nanoparticles, the hydrogen fuel economy, and polymer self-assembly. She has 30 scholarly publications in peer reviewed journals (h-index of 13) and more than 88 scholarly citations including conference papers. Her research programs are aimed at attracting and retaining a diverse population of students to the sciences using societally relevant energy-related and biomedical-related topics. Her work on smart tunable nanomaterials for laser photo thermal therapy (LPPT) has been widely used to train undergraduate students in materials synthesis and biomedical sciences. Her service roles include membership on the African Light Source Executive Steering Committee; the American Institute of Physics – Task Force for Underrepresentation of African Americans in Physics; the American Physical Society, Forum on International Physics; and the National Synchrotron Light Source Executive Users Committee.
Mari Rhodehamel Yin
Treasurer
Mari is the treasurer at Sentrimed and is responsible for overseeing the financial operations of the company including assets from NIH grants and other funding. Upon starting with Sentrimed, she has been responsible for implementing accounting controls and oversight with an ongoing focus on risk management and process optimization. Prior to joining Sentrimed, she had over twenty years of management consulting experience in designing and implementing employee compensation structures for the global pharmaceutical and health insurance industries. Mari ensured companies could rapidly update employee compensation due to ever changing marketplace conditions such as a production difficulties, rollout of new products, and merging of companies. This was done while ensuring expeditious and accurate payroll execution with enhanced job satisfaction and company morale. Her experience also encompasses budget, vendor and contract management, forecasting, and organization optimization. Mari earned her Master of Science in Information Systems from Drexel University and her Bachelor of Arts in Political Science from Hiram College.
Christopher Leonard
Secretary
Chris Leonard has been working as a science specialist in Boston Public Schools since 2010. Previously, he spent 25 years with the community organization, ACORN, holding several positions, including Head Organizer (director) Massachusetts and D.C. chapters and Massachusetts Campaign Director. In his capacity as head organizer, his responsibilities included overseeing the organization’s finances and staffing and working with the board of directors. While Massachusetts Campaign Director, he ran a successful statewide campaign to enact predatory lending legislation in 2004. Chris is an early investor in the company and has previously served as President.